Literature DB >> 26248553

High nuclear expression of protein arginine methyltransferase-5 is a potentially useful marker to estimate submucosal invasion in endoscopically resected early colorectal carcinoma.

Min Gyoung Pak1, Hyoun Wook Lee2, Mee Sook Roh1.   

Abstract

Protein arginine methyltransferase-5 (PRMT5), a major type II arginine methyltransferase, is an important epigenetic modifier with oncogene-like properties because of its ability to repress the expression of tumor suppressor genes. We determined the correlations between PRMT5 expression or its cellular localization and malignant progression, with special reference to invasiveness, in colorectal adenomas and early colorectal carcinomas (CRCs). We performed immunohistochemical detection of PRMT5 in 108 endoscopically resected tissue samples (6 adenomas with low-grade dysplasia, 34 adenomas with high-grade dysplasia, 30 intramucosal carcinomas, and 38 submucosal invasive carcinomas). Early CRC (55 of 68, 80.9%) showed more frequent nuclear expression of PRMT5 than adenoma (15 of 40, 37.5%) (P < 0.001). Furthermore, high (strong staining in ≥ 50% of nuclei) nuclear expression of PRMT5 was more common in submucosal invasive carcinoma (21 of 38, 55.3%) than in intramucosal carcinoma (9 of 30, 30.0%) (P = 0.037). In conclusion, our data suggests that high nuclear expression of PRMT5 is a potentially useful marker for estimating submucosal invasion of early CRC in endoscopically resected specimens.
© 2015 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  adenoma; early colorectal carcinoma; endoscopic treatment; protein arginine methyltransferase-5; submucosal invasion

Mesh:

Substances:

Year:  2015        PMID: 26248553     DOI: 10.1111/pin.12338

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  4 in total

1.  Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status.

Authors:  Bhavna Kumar; Arti Yadav; Nicole V Brown; Songzhu Zhao; Michael J Cipolla; Paul E Wakely; Alessandra C Schmitt; Robert A Baiocchi; Theodoros N Teknos; Matthew Old; Pawan Kumar
Journal:  Oncotarget       Date:  2017-02-28

2.  PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.

Authors:  Liu Yang; Da-Wei Ma; Yue-Peng Cao; Dong-Zheng Li; Xin Zhou; Ji-Feng Feng; Jun Bao
Journal:  Theranostics       Date:  2021-01-27       Impact factor: 11.556

Review 3.  Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review.

Authors:  Kavanya Feustel; Gerald S Falchook
Journal:  J Immunother Precis Oncol       Date:  2022-06-22

4.  PRMT5 promotes DNA repair through methylation of 53BP1 and is regulated by Src-mediated phosphorylation.

Authors:  Jee Won Hwang; Su-Nam Kim; Nayeon Myung; Doona Song; Gyoonhee Han; Gyu-Un Bae; Mark T Bedford; Yong Kee Kim
Journal:  Commun Biol       Date:  2020-08-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.